SG10201804021TA - Methods of preparing inhibitors of influenza viruses replication - Google Patents

Methods of preparing inhibitors of influenza viruses replication

Info

Publication number
SG10201804021TA
SG10201804021TA SG10201804021TA SG10201804021TA SG10201804021TA SG 10201804021T A SG10201804021T A SG 10201804021TA SG 10201804021T A SG10201804021T A SG 10201804021TA SG 10201804021T A SG10201804021T A SG 10201804021TA SG 10201804021T A SG10201804021T A SG 10201804021TA
Authority
SG
Singapore
Prior art keywords
compound
methods
influenza viruses
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
SG10201804021TA
Inventor
Gerald Tanoury
William Nugent
Vadims Dvornikovs
Peter Rose
Original Assignee
Vertex Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vertex Pharma filed Critical Vertex Pharma
Publication of SG10201804021TA publication Critical patent/SG10201804021TA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00—Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/02—Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides
    • B01J31/04—Catalysts comprising hydrides, coordination complexes or organic compounds containing organic compounds or metal hydrides containing carboxylic acids or their salts
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2231/00—Catalytic reactions performed with catalysts classified in B01J31/00
    • B01J2231/40—Substitution reactions at carbon centres, e.g. C-C or C-X, i.e. carbon-hetero atom, cross-coupling, C-H activation or ring-opening reactions
    • B01J2231/44—Allylic alkylation, amination, alkoxylation or analogues
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00—Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/80—Complexes comprising metals of Group VIII as the central metal
    • B01J2531/82—Metals of the platinum group
    • B01J2531/824—Palladium
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Abstract

METHODS OF PREPARING INHIBITORS OF INFLUENZA VIRUSES REPLICATION A method of preparing Compound (1) or a pharmaceutically acceptable salt thereof: comprises: (a) reacting Compound (X): a pharmaceutically acceptable salt thereof with Compound (Y): in the presence of a palladium catalyst and a carbonate orphosphate base to form compound (Z): or a pharmaceutically acceptable salt thereof; and (b) deprotecting the Ts group of Compound(Z) to form Compound (1) or a pharmaceutically acceptable salt thereof.
SG10201804021TA 2013-11-13 2014-11-12 Methods of preparing inhibitors of influenza viruses replication SG10201804021TA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361903893P 2013-11-13 2013-11-13

Publications (1)

Publication Number Publication Date
SG10201804021TA true SG10201804021TA (en) 2018-07-30

Family

ID=51952044

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201804021TA SG10201804021TA (en) 2013-11-13 2014-11-12 Methods of preparing inhibitors of influenza viruses replication

Country Status (24)

Country Link
US (3) US10023569B2 (en)
EP (3) EP3421468B1 (en)
JP (3) JP6618901B2 (en)
KR (1) KR102338461B1 (en)
CN (2) CN105849105B (en)
AU (3) AU2014348752C1 (en)
BR (1) BR112016010576B1 (en)
CA (1) CA2930297C (en)
CY (1) CY1121074T1 (en)
DK (2) DK3421468T3 (en)
ES (2) ES2684755T3 (en)
HR (2) HRP20181272T1 (en)
HU (2) HUE052178T2 (en)
IL (2) IL245586B (en)
LT (2) LT3068782T (en)
MX (1) MX2016006200A (en)
PL (1) PL3068782T3 (en)
PT (1) PT3068782T (en)
RS (1) RS57541B1 (en)
RU (2) RU2019104421A (en)
SG (1) SG10201804021TA (en)
SI (2) SI3421468T1 (en)
WO (1) WO2015073481A1 (en)
ZA (1) ZA201603132B (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3141252T3 (en) 2009-06-17 2018-11-19 Vertex Pharma INHIBITORS OF INFLUENZA VIRUS REPLICATION
UA118010C2 (en) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед INFLUENCES OF INFLUENZA VIRUS REPLICATION
US9296727B2 (en) 2013-10-07 2016-03-29 Vertex Pharmaceuticals Incorporated Methods of regioselective synthesis of 2,4-disubstituted pyrimidines
EP3421468B1 (en) 2013-11-13 2020-11-04 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
MX2016006199A (en) 2013-11-13 2016-08-08 Vertex Pharma Inhibitors of influenza viruses replication.
JP6704416B2 (en) 2015-05-13 2020-06-03 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Methods for preparing inhibitors of influenza virus replication
MA42422A (en) 2015-05-13 2018-05-23 Vertex Pharma INHIBITORS OF INFLUENZA VIRUS REPLICATION
JP6952695B2 (en) * 2015-12-09 2021-10-20 サンシャイン・レイク・ファーマ・カンパニー・リミテッドＳｕｎｓｈｉｎｅ Ｌａｋｅ Ｐｈａｒｍａ Ｃｏ．，Ｌｔｄ． Influenza virus replication inhibitors, their application and use
CN107759571B (en) 2016-08-16 2021-03-02 广东东阳光药业有限公司 Inhibitors of influenza virus replication and methods of use and uses thereof
CN109641868B (en) 2016-08-30 2021-12-03 广东东阳光药业有限公司 Inhibitors of influenza virus replication and methods of use and uses thereof
CN108218873B (en) 2016-12-15 2020-07-07 广东东阳光药业有限公司 Inhibitors of influenza virus replication and uses thereof
WO2018127096A1 (en) 2017-01-05 2018-07-12 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication and uses thereof
WO2018157830A1 (en) 2017-03-02 2018-09-07 Sunshine Lake Pharma Co., Ltd. Inhibitors of influenza virus replication and uses thereof
TWI778052B (en) * 2017-04-24 2022-09-21 美商共結晶製藥公司 Inhibitors of influenza virus replication
CA3094588A1 (en) * 2018-04-06 2019-10-10 Janssen Pharmaceuticals, Inc. Isothermal reactive crystallisation process for the preparation of a crystalline form of pimodivir hydrochloride hemihydrate
US20200397784A1 (en) * 2019-06-20 2020-12-24 Janssen Pharmaceuticals, Inc. Formulations of azaindole compounds
WO2021038480A1 (en) 2019-08-27 2021-03-04 Janssen Pharmaceuticals, Inc. Combinations for treating influenza virus
CN111454166B (en) * 2019-12-30 2021-02-26 广东莱佛士制药技术有限公司 Process for the preparation of (2S,3S) -3-amino-bicyclo [2.2.2] octane-2-carboxylate
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus

Family Cites Families (175)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1115212A (en) * 1978-02-10 1981-12-29 Emilio Kyburz Pyrrolidine derivatives
US4349552A (en) * 1978-10-30 1982-09-14 Fujisawa Pharmaceutical Company, Ltd. 5-Fluorouracil derivatives, and their pharmaceutical compositions
JPS5581865A (en) * 1978-10-30 1980-06-20 Fujisawa Pharmaceut Co Ltd 5-fluorouracil derivatives and their preparation
NZ221717A (en) 1986-09-10 1990-08-28 Sandoz Ltd Azaindole and indolizine derivatives and pharmaceutical compositions
MX19185A (en) 1989-01-20 1993-12-01 Pfizer PROCEDURE FOR PREPARING 3- (1,2,5,6-TRETRAHIDROPIRIDIL) -PIRROLOPIRIDINAS.
US5304121A (en) 1990-12-28 1994-04-19 Boston Scientific Corporation Drug delivery system making use of a hydrogel polymer coating
FR2687402B1 (en) 1992-02-14 1995-06-30 Lipha NOVEL AZAINDOLES, METHODS OF PREPARATION AND MEDICAMENTS CONTAINING THEM.
DE4304455A1 (en) 1993-02-15 1994-08-18 Bayer Ag Heterocyclic substituted phenyl-cyclohexane-carboxylic acid derivatives
US5994341A (en) 1993-07-19 1999-11-30 Angiogenesis Technologies, Inc. Anti-angiogenic Compositions and methods for the treatment of arthritis
IL129871A (en) 1994-05-06 2003-11-23 Pharmacia & Upjohn Inc Process for preparing 4-phenyl-substituted octanoyl-oxazolidin-2-one intermediates that are useful for preparing pyran-2-ones useful for treating retroviral infections
US6075037A (en) 1994-06-09 2000-06-13 Smithkline Beecham Corporation Endothelin receptor antagonists
US6099562A (en) 1996-06-13 2000-08-08 Schneider (Usa) Inc. Drug coating with topcoat
US5821243A (en) 1996-07-22 1998-10-13 Viropharma Incorporated Compounds compositions and methods for treating influenza
GB9721437D0 (en) 1997-10-10 1997-12-10 Glaxo Group Ltd Heteroaromatic compounds and their use in medicine
HUP0200309A3 (en) 1999-01-07 2003-05-28 Wyeth Corp Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression, process for their preparation and pharmaceutical compositions containing them
US6313126B1 (en) 1999-01-07 2001-11-06 American Home Products Corp Arylpiperazinyl-cyclohexyl indole derivatives for the treatment of depression
AU2494300A (en) 1999-01-07 2000-07-24 American Home Products Corporation 3,4-dihydro-2h-benzo(1,4)oxazine derivatives
US6265403B1 (en) 1999-01-20 2001-07-24 Merck & Co., Inc. Angiogenesis inhibitors
AR028475A1 (en) 1999-04-22 2003-05-14 Wyeth Corp DERIVATIVES OF AZAINDOL AND USE OF THE SAME FOR THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF DEPRESSION.
US20030153560A1 (en) 1999-04-23 2003-08-14 Salituro Francesco G. Inhibitors of c-Jun N-terminal kinases (JNK)
ATE323482T1 (en) 1999-07-02 2006-05-15 Stuart A Lipton USE OF P38 MAPK INHIBITORS IN THE TREATMENT OF EYE DISEASES
GB9919843D0 (en) 1999-08-20 1999-10-27 Smithkline Beecham Plc Novel compounds
DE19948417A1 (en) 1999-10-07 2001-04-19 Morphochem Ag Imidazole derivatives and their use as medicines
US20020065270A1 (en) 1999-12-28 2002-05-30 Moriarty Kevin Joseph N-heterocyclic inhibitors of TNF-alpha expression
AU3704101A (en) 2000-02-17 2001-08-27 Amgen Inc Kinase inhibitors
US7041277B2 (en) 2000-03-10 2006-05-09 Cadbury Adams Usa Llc Chewing gum and confectionery compositions with encapsulated stain removing agent compositions, and methods of making and using the same
CA2308994A1 (en) 2000-05-19 2001-11-19 Aegera Therapeutics Inc. Neuroprotective compounds
PT1309592E (en) 2000-08-14 2006-07-31 Ortho Mcneil Pharm Inc SUBSTITUTED PYRAZOLES
JP4129391B2 (en) 2000-09-06 2008-08-06 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド How to treat allergies with substituted pyrazoles
EP1315741A2 (en) 2000-09-06 2003-06-04 Ortho-McNeil Pharmaceutical, Inc. A method for treating allergies
AR031130A1 (en) 2000-09-20 2003-09-10 Abbott Lab PROMOTING N-ACILSULFONAMIDS OF APOPTOSIS
EP1355904B1 (en) 2000-12-22 2007-08-01 Wyeth Heterocyclindazole and azaindazole compounds as 5-hydroxytryptamine-6 ligands
CA2439263C (en) 2001-03-02 2012-10-23 Frank Becker Three hybrid assay system
ATE281459T1 (en) 2001-03-14 2004-11-15 Wyeth Corp AZAHETEROCYCLYLMETHYL DERIVATIVES OF 2,3-DIHYDRO-1,4-DIOXINO(2,3-F)QUINOLINE AS ANTIDEPRESSANTS
US7081454B2 (en) 2001-03-28 2006-07-25 Bristol-Myers Squibb Co. Tyrosine kinase inhibitors
WO2002085896A1 (en) 2001-04-24 2002-10-31 Wyeth Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-benzodioxan
US6656950B2 (en) 2001-04-25 2003-12-02 Wyeth Antidepressant azaheterocyclylmethyl derivatives of 1,4-dioxino[2,3-b]pyridine
WO2002088135A1 (en) 2001-04-26 2002-11-07 Wyeth Antidepressant azaheterocyclylmethyl derivatives of oxaheterocycle-fused-[1,4]-benzodioxans
US6593350B2 (en) 2001-04-26 2003-07-15 Wyeth Antidepressant indoletetrahydropyridine derivatives of 2,3-dihydro-7H-[1,4]dioxino[2,3-e]indole
WO2002088129A1 (en) 2001-04-26 2002-11-07 Wyeth Antidepressant azaheterocyclylmethyl derivatives of 2,3-dihydro-1,4-dioxino[2,3-f]quinazoline
BR0209408A (en) 2001-04-26 2004-07-06 Wyeth Corp Azaheterocyclylmethyl antidepressants derived from 7,8-dihydro-3h-6,9-dioxa-1,3-diaza-cyclopenta [a] naphthalene and method of treatment using such compounds and process for preparing them
EP1381614B1 (en) 2001-04-26 2006-08-02 Wyeth ANTIDEPRESSANT AZAHETEROCYCLYLMETHYL DERIVATIVES OF 2,3-DIHYDRO-1,4-DIOXINO¬2,3-f|QUINOXALINE
TR200402753T4 (en) 2001-04-30 2004-11-22 Wyeth Antidepressant azaheterocyclmethyl derivatives of 7,8-dihydro-1,6,9-trioxa-3-aza-cyclopenta [a] naphthalene.
US6555560B2 (en) 2001-04-30 2003-04-29 Wyeth Antidepressant azaheterocyclylmethyl derivatives of 1,4,5-trioxa-phenanthrene
GB0111186D0 (en) 2001-05-08 2001-06-27 Smithkline Beecham Plc Novel compounds
WO2002092602A2 (en) 2001-05-17 2002-11-21 Wyeth PROCESSES FOR THE SYNTHESIS OF DERIVATIVES OF 2,3-DIHYDRO-1,4-DIOXINO-[2,3-f] QUINOLINE
EP1399440B1 (en) 2001-06-15 2009-06-03 Vertex Pharmaceuticals Incorporated 5-(2-aminopyrimidin-4-yl)benzisoxazoles as protein kinase inhibitors
GB0115109D0 (en) 2001-06-21 2001-08-15 Aventis Pharma Ltd Chemical compounds
AR035083A1 (en) 2001-07-25 2004-04-14 Wyeth Corp AZAHETEROCICLILMETILIC DERIVATIVES OF 7,8-DIHIDRO-6H-5-OXA-1-AZA-FENANTRENE, PHARMACEUTICAL COMPOSITIONS, THE USE OF SUCH DERIVATIVES FOR THE PREPARATION OF AN ANTIDEPRESSIVE AND INTERMEDIARY MEDICINAL PRODUCT
MXPA04001361A (en) 2001-08-14 2004-05-27 Toyama Chemical Co Ltd Novel virus proliferation inhibition/virucidal method and novel pyradine nucleotide/pyradine nucleoside analogue.
US20040236110A1 (en) 2001-09-26 2004-11-25 Ladouceur Gaetan H Substituted 3-pyridyl indoles and indazoles as c17,20 lyase inhibitors
WO2003031439A1 (en) 2001-10-05 2003-04-17 Wyeth Antidepressant chroman and chromene derivatives of 3-(1,2,3,6-tetrahydro-4-pyridinyl)-1h-indole
US7361671B2 (en) 2001-11-15 2008-04-22 The Institute For Pharmaceutical Discovery, Inc. Substituted heteroarylalkanoic acids
TW200306819A (en) 2002-01-25 2003-12-01 Vertex Pharma Indazole compounds useful as protein kinase inhibitors
EP1506189A1 (en) 2002-04-26 2005-02-16 Vertex Pharmaceuticals Incorporated Pyrrole derivatives as inhibitors of erk2 and uses thereof
ATE308544T1 (en) 2002-04-26 2005-11-15 Pfizer Prod Inc N-SUBSTITUIETE HETEROARYLOXY-ARYL-SPIRO-PYRIMIDINE-2,4,6-TRION METALLOPROTEINASE INHIBITORS
TW200406385A (en) 2002-05-31 2004-05-01 Eisai Co Ltd Pyrazole compound and pharmaceutical composition containing the same
UA78999C2 (en) 2002-06-04 2007-05-10 Wyeth Corp 1-(aminoalkyl)-3-sulfonylazaindoles as ligands of 5-hydroxytryptamine-6
PT1532145E (en) 2002-08-02 2007-01-31 Vertex Pharma Pyrazole compositions useful as inhibitors of gsk-3
WO2004014912A1 (en) 2002-08-08 2004-02-19 Ribapharm Inc. Improved synthesis for hydroxyalkylated heterocyclic bases
SE0202463D0 (en) 2002-08-14 2002-08-14 Astrazeneca Ab Novel compounds
US7262200B2 (en) 2002-10-25 2007-08-28 Vertex Pharmaceuticals Incorporated Indazolinone compositions useful as kinase inhibitors
KR100983462B1 (en) 2003-02-26 2010-09-27 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 Dihydropteridinones, method for the production and use thereof in the form of drugs
EP2295433A3 (en) 2003-03-06 2011-07-06 Eisai R&D Management Co., Ltd. JNK inhibitors
KR20050122210A (en) 2003-03-17 2005-12-28 다케다 샌디에고, 인코포레이티드 Histone deacetylase inhibitors
GB0308466D0 (en) 2003-04-11 2003-05-21 Novartis Ag Organic compounds
WO2005000813A1 (en) 2003-05-30 2005-01-06 Imclone Systems Incorporated Heteroarylamino-phenylketone derivatives and their use as kinase inhibitors
WO2004106298A1 (en) 2003-05-30 2004-12-09 Janssen Pharmaceutica N.V. Indole derivatives with an improved antipsychotic activity
EP1781659B1 (en) 2003-07-16 2008-11-05 Janssen Pharmaceutica N.V. Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors
TWI339206B (en) 2003-09-04 2011-03-21 Vertex Pharma Compositions useful as inhibitors of protein kinases
WO2005044181A2 (en) 2003-09-09 2005-05-19 Temple University-Of The Commonwealth System Of Higher Education Protection of tissues and cells from cytotoxic effects of ionizing radiation by abl inhibitors
JP2007507529A (en) 2003-09-30 2007-03-29 サイオス・インコーポレーテツド Heterocyclic amides and sulfonamides
CN1897950A (en) 2003-10-14 2007-01-17 惠氏公司 Fused-aryl and heteroaryl derivatives and methods of their use
AU2004308299B2 (en) 2003-12-19 2011-11-24 Plexxikon, Inc. Compounds and methods for development of Ret modulators
US20070066641A1 (en) 2003-12-19 2007-03-22 Prabha Ibrahim Compounds and methods for development of RET modulators
GB0405055D0 (en) 2004-03-05 2004-04-07 Eisai London Res Lab Ltd JNK inhibitors
KR101298967B1 (en) 2004-03-30 2013-09-02 버텍스 파마슈티칼스 인코포레이티드 Azaindoles useful as inhibitors of JAK and other protein kinases
FR2868422B1 (en) * 2004-03-31 2006-07-14 Aventis Pharma Sa NOVEL PYRROLO (2,3-B) PYRIDINE DERIVATIVES, THEIR PREPARATION AND THEIR PHARMACEUTICAL USE AS INHIBITORS OF KINASES
KR20070002081A (en) 2004-04-02 2007-01-04 버텍스 파마슈티칼스 인코포레이티드 Azaindoles useful as inhibitors of rock and other protein kinases
ITMI20040874A1 (en) 2004-04-30 2004-07-30 Ist Naz Stud Cura Dei Tumori INDOLIC AND AZAINDOLIC DERIVATIVES WITH ANTI-TUMORAL ACTION
KR100476851B1 (en) 2004-05-18 2005-03-17 (주)성신엔지니어링 Gravity Flow filter using Fiber medium
JP2007538068A (en) * 2004-05-19 2007-12-27 アストラゼネカ アクチボラグ Novel fused heterocycles and their use
WO2006009755A2 (en) 2004-06-17 2006-01-26 Plexxikon, Inc. Azaindoles modulating c-kit activity and uses therefor
DE102004029784A1 (en) 2004-06-21 2006-01-05 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel 2-Benzylaminodihydropteridinones, process for their preparation and their use as medicaments
US20050288290A1 (en) 2004-06-28 2005-12-29 Borzilleri Robert M Fused heterocyclic kinase inhibitors
US20060122213A1 (en) 2004-06-30 2006-06-08 Francoise Pierard Azaindoles useful as inhibitors of protein kinases
US7361763B2 (en) 2004-07-27 2008-04-22 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
FR2876103B1 (en) * 2004-10-01 2008-02-22 Aventis Pharma Sa NOVEL BIS-AZAINDOL DERIVATIVES, THEIR PREPARATION AND THEIR PHARMACEUTICAL USE AS INHIBITORS OF KINASES
EP1799684B1 (en) 2004-10-04 2014-12-03 Millennium Pharmaceuticals, Inc. Lactam compounds useful as protein kinase inhibitors
WO2006038001A1 (en) 2004-10-06 2006-04-13 Celltech R & D Limited Aminopyrimidine derivatives as jnk inhibitors
US7855205B2 (en) 2004-10-29 2010-12-21 Janssen Pharmaceutica Nv Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
KR20070090172A (en) 2004-11-04 2007-09-05 버텍스 파마슈티칼스 인코포레이티드 Pyrazolo[1,5-a]pyrimidines useful as inhibitors of protein kinases
CN101098872B (en) 2004-11-22 2012-09-05 沃泰克斯药物股份有限公司 Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases
SI2377557T1 (en) 2004-11-24 2017-02-28 Meda Pharmaceuticals Inc. Compositions comprising azelastine and methods of use thereof
JP4954086B2 (en) 2004-12-08 2012-06-13 グラクソスミスクライン・リミテッド・ライアビリティ・カンパニー 1H-pyrrolo [2,3-B] pyridine
MX2007007330A (en) 2004-12-16 2007-10-04 Vertex Pharma Pyrid-2-ones useful as inhibitors of tec family protein kinases for the treatment of inflammatory, proliferative and immunologically-mediated diseases.
US20060161001A1 (en) 2004-12-20 2006-07-20 Amgen Inc. Substituted heterocyclic compounds and methods of use
US8633205B2 (en) 2005-02-03 2014-01-21 Vertex Pharmaceuticals Incorporated Substituted pyrrolo[2,3-d]pyrimidines as inhibitors of protein kinases
BRPI0610828A2 (en) 2005-05-16 2010-07-27 Irm Llc compounds and compositions as protein kinase inhibitors
MX2007014619A (en) 2005-05-20 2009-02-13 Vertex Pharma Pyrrolopyridines useful as inhibitors of protein kinase.
EP2395004B1 (en) 2005-06-22 2016-01-20 Plexxikon Inc. Pyrrolo [2,3-b]pyridine derivatives as protein kinase inhibitors
EP1749523A1 (en) 2005-07-29 2007-02-07 Neuropharma, S.A. GSK-3 inhibitors
GB0516156D0 (en) 2005-08-05 2005-09-14 Eisai London Res Lab Ltd JNK inhibitors
CN101801971A (en) 2005-09-30 2010-08-11 沃泰克斯药物股份有限公司 Deazapurines useful as inhibitors of janus kinases
CA2628179A1 (en) 2005-11-15 2007-05-24 Vertex Pharmaceuticals Incorporated Azaindazoles useful as inhibitors of kinases
US20130096302A1 (en) 2005-11-22 2013-04-18 Hayley Binch Pyrrolopyrazines and pyrazolopyrazines useful as inhibitors of protein kinases
EP1973911B1 (en) 2006-01-17 2016-01-13 Vertex Pharmaceuticals Incorporated Azaindoles useful for the treatment of (inter alia) proliferative, cardiac, neurodegenerative, autoimmune or inflammatory disorders
NZ570530A (en) 2006-02-14 2011-09-30 Vertex Pharma Pharmaceutical compositions comprising 6-oxo-6,7,8,9-tetrahydro-5H-pyrimido[4,5-b][1,4)diazepine derivatives
US7659283B2 (en) 2006-02-14 2010-02-09 Vertex Pharmaceuticals Incorporated Pyrrolo [3,2-C] pyridines useful as inhibitors of protein kinases
DE102006012617A1 (en) 2006-03-20 2007-09-27 Merck Patent Gmbh 4- (pyrrolopyridinyl) -pyrimidinyl-2-amine derivatives
AU2007235558B2 (en) * 2006-03-24 2011-12-01 Array Biopharma Inc. 2 -aminopyridine analogs as glucokinase activators
SG170828A1 (en) 2006-04-05 2011-05-30 Vertex Pharmaceuticals Inc Us Deazapurines useful as inhibitors of janus kinases
MX2008013582A (en) 2006-04-26 2009-01-19 Hoffmann La Roche Pyrimidine derivatives as pi3k inhibitors.
PL2041139T3 (en) 2006-04-26 2012-05-31 Hoffmann La Roche Pharmaceutical compounds
WO2007129195A2 (en) 2006-05-04 2007-11-15 Pfizer Products Inc. 4-pyrimidine-5-amino-pyrazole compounds
WO2007146057A2 (en) 2006-06-09 2007-12-21 Wisconsin Alumni Research Foundation Screening method for modulators of viral transcription or replication
WO2008005457A2 (en) 2006-06-30 2008-01-10 Sunesis Pharmaceuticals Pyridinonyl pdk1 inhibitors
US20080090834A1 (en) * 2006-07-06 2008-04-17 Pfizer Inc Selective azole pde10a inhibitor compounds
TW200808325A (en) 2006-07-06 2008-02-16 Astrazeneca Ab Novel compounds
WO2008018426A1 (en) 2006-08-08 2008-02-14 Chugai Seiyaku Kabushiki Kaisha Pyrimidine derivative as pi3k inhibitor and use thereof
AU2007287428B2 (en) 2006-08-24 2011-08-11 Astrazeneca Ab Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders
US20130310418A1 (en) 2006-11-15 2013-11-21 Vertex Pharmaceuticals Incorporated Azaindazoles useful as inhibitors of kinases
JP5406725B2 (en) 2006-12-14 2014-02-05 バーテックス ファーマシューティカルズ インコーポレイテッド Compounds useful as protein kinase inhibitors
CN101678022A (en) 2006-12-21 2010-03-24 弗特克斯药品有限公司 5-cyano group-4-(pyrrolo-[2, the 3b] pyridin-3-yl) pyrimidine derivatives that can be used as kinases inhibitor
TW200840581A (en) 2007-02-28 2008-10-16 Astrazeneca Ab Novel pyrimidine derivatives
ES2435997T3 (en) 2007-03-09 2013-12-26 Vertex Pharmaceuticals, Inc. Aminopyrimidines useful as protein kinase inhibitors
NZ579485A (en) 2007-03-09 2012-02-24 Vertex Pharma Aminopyrimidines useful as inhibitors of protein kinases
EP2134709A1 (en) 2007-03-09 2009-12-23 Vertex Pharmaceuticals, Inc. Aminopyridines useful as inhibitors of protein kinases
KR101157848B1 (en) 2007-03-22 2012-07-11 다케다 야쿠힌 고교 가부시키가이샤 Substituted pyrimidodiazepines useful as plk1 inhibitors
UA100120C2 (en) * 2007-04-03 2012-11-26 Анадис Фармасьютикалз, Инк. 5,6-dihydro-1h-pyridin-2-one compounds
RU2334747C1 (en) 2007-04-05 2008-09-27 Андрей Александрович Иващенко SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-PYRIDO[4,3-b]INDOLES, METHOD OF PRODUCTION AND APPLICATION THEREOF
RU2339637C1 (en) 2007-04-05 2008-11-27 Андрей Александрович Иващенко Histamine receptor blockers for pharmaceutical compositions of antiallergic and autoimmune effect
CA2694499A1 (en) 2007-07-31 2009-02-05 Vertex Pharmaceuticals Incorporated Process for preparing 5-fluoro-1h-pyrazolo [3, 4-b] pyridin-3-amine and derivatives thereof
CA2695753A1 (en) 2007-08-15 2009-02-19 Vertex Pharmaceuticals Incorporated Compounds useful as protein kinases inhibitors
EP2205603B1 (en) 2007-09-28 2014-01-15 Cyclacel Limited Pyrimidine derivatives as protein kinase inhibitors
AU2008309939B2 (en) 2007-10-09 2013-11-14 European Molecular Biology Laboratory (Embl) Soluble fragments of influenza virus PB2 protein capable of binding RNA-cap
AU2008331733A1 (en) 2007-11-02 2009-06-11 Vertex Pharmaceuticals Incorporated [1H- pyrazolo [3, 4-b] pyridine-4-yl] -phenyle or -pyridin-2-yle derivatives as protein kinase C-theta
WO2009059943A1 (en) 2007-11-05 2009-05-14 Novartis Ag 4-benzylamino-1-carboxyacyl-piperidine derivatives as cetp inhibitors useful for the treatment of diseases such as hyperlipidemia or arteriosclerosis
JP5368485B2 (en) 2008-02-25 2013-12-18 エフ．ホフマン−ラ ロシュ アーゲー Pyrrolopyrazine kinase inhibitor
JP2011513483A (en) 2008-03-10 2011-04-28 バーテックス ファーマシューティカルズ インコーポレイテッド Pyrimidines and pyridines useful as inhibitors of protein kinases
US20110033473A1 (en) 2008-04-09 2011-02-10 Yoram Reiter Anti influenza antibodies and uses thereof
EP2318412B1 (en) 2008-06-23 2013-08-14 Vertex Pharmceuticals Incorporated Protein kinase inhibitors
AU2009271658B2 (en) 2008-06-23 2014-04-10 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors
US8569337B2 (en) 2008-07-23 2013-10-29 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
MX2011000839A (en) 2008-07-23 2011-04-05 Vertex Pharma Pyrazolopyridine kinase inhibitors.
WO2010011768A1 (en) 2008-07-23 2010-01-28 Vertex Pharmaceuticals Incorporated Tri-cyclic pyrazolopyridine kinase inhibitors
AU2009274017A1 (en) 2008-07-23 2010-01-28 Vertex Pharmaceuticals Incorporated Pyrazolopyridine kinase inhibitors
CA2738929A1 (en) 2008-10-17 2010-04-22 Boehringer Ingelheim International Gmbh Heteroaryl substituted indole compounds useful as mmp-13 inhibitors
EP2427464A1 (en) 2009-05-06 2012-03-14 Vertex Pharmaceuticals Incorporated Pyrazolopyridines
US20120093738A1 (en) 2009-06-11 2012-04-19 Rubicon Research Private Limited Taste-masked oral formulations of influenza antivirals
DK3141252T3 (en) 2009-06-17 2018-11-19 Vertex Pharma INHIBITORS OF INFLUENZA VIRUS REPLICATION
WO2011000566A2 (en) 2009-06-30 2011-01-06 Savira Pharmaceuticals Gmbh Compounds and pharmaceutical compositions for the treatment of negative-sense ssrna virus infections
CN102471339A (en) 2009-07-15 2012-05-23 雅培制药有限公司 Pyrrolopyridine inhibitors of kinases
PL3290428T3 (en) 2010-03-31 2022-02-07 Gilead Pharmasset Llc Tablet comprising crystalline (s)-isopropyl 2-(((s)-(((2r,3r,4r,5r)-5-(2,4-dioxo-3,4-dihydropyrimidin-1 (2h)-yl)-4-fluoro-3-hydroxy-4-methyltetrahydrofuran-2-yl)methoxy)(phenoxy)phosphoryl)amino)propanoate
NZ602795A (en) 2010-04-07 2015-01-30 Vertex Pharma Solid forms of 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-yl) cyclopropanecarboxamido)-3-methylpyridin-2-yl)benzoic acid
CA2796388A1 (en) 2010-04-14 2011-10-20 Array Biopharma Inc. 5, 7-substituted-imidazo [1, 2-c] pyrimidines as inhibitors of jak kinases
WO2011137022A1 (en) * 2010-04-27 2011-11-03 Merck Sharp & Dohme Corp. Azaindoles as janus kinase inhibitors
KR20130128436A (en) 2010-12-16 2013-11-26 버텍스 파마슈티칼스 인코포레이티드 Inhibitors of influenza viruses replication
WO2012083122A1 (en) 2010-12-16 2012-06-21 Vertex Pharmaceutical Incorporated Inhibitors of influenza viruses replication
CA2822057A1 (en) * 2010-12-16 2012-06-21 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
JP2014520815A (en) 2011-07-05 2014-08-25 バーテックス ファーマシューティカルズ インコーポレイテッド Methods and intermediates for making azaindoles
UA118010C2 (en) * 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед INFLUENCES OF INFLUENZA VIRUS REPLICATION
MX2014005565A (en) 2011-11-07 2014-05-30 Vertex Pharma Methods for treating inflammatory diseases and pharmaceutical combinations useful therefor.
WO2013184985A1 (en) 2012-06-08 2013-12-12 Vertex Pharmaceuticals Incorporated Inhibitors of influenza viruses replication
WO2014201332A1 (en) 2013-06-14 2014-12-18 Vertex Pharmaceuticals Incorporated Pharmaceutical combinations useful for treating rheumatoid arthritis
KR20160045070A (en) 2013-08-22 2016-04-26 버텍스 파마슈티칼스 인코포레이티드 Isotopically enriched azaindoles
US9296727B2 (en) 2013-10-07 2016-03-29 Vertex Pharmaceuticals Incorporated Methods of regioselective synthesis of 2,4-disubstituted pyrimidines
JP2016537347A (en) 2013-11-13 2016-12-01 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Formulation of azaindole compounds
MX2016006199A (en) 2013-11-13 2016-08-08 Vertex Pharma Inhibitors of influenza viruses replication.
EP3421468B1 (en) 2013-11-13 2020-11-04 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
MA40773A (en) 2014-10-02 2017-08-08 Vertex Pharma INFLUENZA A VIRUS VARIANTS
MA40772A (en) 2014-10-02 2017-08-08 Vertex Pharma INFLUENZA A VIRUS VARIANTS
JP6704416B2 (en) 2015-05-13 2020-06-03 バーテックス ファーマシューティカルズ インコーポレイテッドＶｅｒｔｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃｏｒｐｏｒａｔｅｄ Methods for preparing inhibitors of influenza virus replication
CN110603041A (en) 2017-04-12 2019-12-20 沃泰克斯药物股份有限公司 Combination therapy for the treatment of influenza virus infections

Also Published As

Publication number Publication date
KR102338461B1 (en) 2021-12-13
AU2021204970A1 (en) 2021-08-05
CN105849105A (en) 2016-08-10
IL245586B (en) 2020-05-31
RU2019104421A (en) 2019-04-17
CN105849105B (en) 2018-02-13
JP2021155459A (en) 2021-10-07
US10640501B2 (en) 2020-05-05
JP6618901B2 (en) 2019-12-11
AU2014348752B2 (en) 2019-02-28
RU2680800C1 (en) 2019-02-27
EP3421468A2 (en) 2019-01-02
HRP20210029T1 (en) 2021-03-19
SI3068782T1 (en) 2018-10-30
WO2015073481A1 (en) 2015-05-21
IL245586A0 (en) 2016-06-30
RS57541B1 (en) 2018-10-31
DK3421468T3 (en) 2021-01-11
BR112016010576A2 (en) 2017-08-08
BR112016010576B1 (en) 2022-05-24
AU2019203656A1 (en) 2019-06-13
LT3421468T (en) 2021-01-11
DK3068782T3 (en) 2018-08-13
RU2016122903A (en) 2017-12-18
JP2019142945A (en) 2019-08-29
CA2930297A1 (en) 2015-05-21
KR20160084466A (en) 2016-07-13
EP3068782B1 (en) 2018-05-23
PL3068782T3 (en) 2018-12-31
EP3421468A3 (en) 2019-02-20
CN108276278A (en) 2018-07-13
HRP20181272T1 (en) 2018-10-05
CN108276278B (en) 2021-04-20
US20180282330A1 (en) 2018-10-04
EP3851437A3 (en) 2021-11-03
CY1121074T1 (en) 2019-12-11
HUE052178T2 (en) 2021-04-28
SI3421468T1 (en) 2021-03-31
AU2014348752C1 (en) 2019-11-21
LT3068782T (en) 2018-09-10
EP3068782A1 (en) 2016-09-21
ZA201603132B (en) 2018-08-29
PT3068782T (en) 2018-10-08
ES2843173T3 (en) 2021-07-16
EP3421468B1 (en) 2020-11-04
CA2930297C (en) 2022-04-05
US10023569B2 (en) 2018-07-17
EP3851437A2 (en) 2021-07-21
ES2684755T3 (en) 2018-10-04
US11345700B2 (en) 2022-05-31
AU2014348752A1 (en) 2016-05-26
US20160251354A1 (en) 2016-09-01
JP2017501120A (en) 2017-01-12
IL274720A (en) 2020-07-30
MX2016006200A (en) 2016-08-08
US20200207765A1 (en) 2020-07-02
HUE038820T2 (en) 2018-11-28

Similar Documents

Publication Publication Date Title
SG10201804021TA (en) Methods of preparing inhibitors of influenza viruses replication
MY182428A (en) Crystalline forms of a prolyl hydroxylase inhibitor
NZ727601A (en) Dihydropyrimido fused ring derivative as hbv inhibitor
MY156715A (en) Method for preparing flavor-containing sheet for smoking article, flavor-containing sheet for smoking article prepared by the method, and smoking article comprising the same
MY167697A (en) Method for producing 4,4-difluoro-3,4- dihydroisoquinoline derivatives
MX2016006199A (en) Inhibitors of influenza viruses replication.
JO3068B1 (en) Imidazopyridazines as AKT Kinase Inhibitors
WO2014153495A9 (en) Novel stat3 inhibitors
MX2015009617A (en) Crystalline forms of {[1-cyano-5-(4-chlorophenoxy)-4-hydroxy-isoq uinoline-3-carbonyl]-amino}-acetic acid.
JO2930B1 (en) New process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
IN2013MU01111A (en)
GB2523674A (en) Compounds as inhibitor of DNA double-strand break repair, methods and applications thereof
IN2014DN10658A (en)
UA111329C2 (en) Process for the synthesis of ivabradine and addition salts thereof with a pharmaceutically acceptable acid
MX2019005723A (en) Fgfr4 inhibitor and preparation method and use thereof.
IN2014DE01203A (en)
MX361000B (en) Amine salts of pitavastatin and rosuvastatin.
IN2013CH04314A (en)
UA117900C2 (en) METHOD OF SYNTHESIS OF 3- (2-BROMO-4,5-DIMETOXIFENIL) PROPANNITRIL AND APPLICATION IN SYNTHESIS OF IVABRADINE AND ITS ADDITIVE SALTS WITH PHARMACEUTICALLY PRACTICE
UA118008C2 (en) METHOD OF SYNTHESIS (2E) -3- (3,4-DIMETOXIFYNEL) PROP-2-ENNITRIL AND APPLICATION IN SYNTHESIS OF IVABRADINE AND ITS ADDITIVE PHARMACYTESE PHARMACEUTICAL SALTS
MX2016002186A (en) Process for preparing dronedarone and salts thereof.
MX2013002990A (en) Novel method for synthesising ivabradine and its pharmaceutically acceptable acid addition salts.
FR3012016B1 (en) PROCESS FOR PREPARING A FOOD COMPOSITION BASED ON CORNICHONS, AND FOOD COMPOSITION OBTAINED THEREBY
MX347536B (en) Process for the enzymatic synthesis of (7s)-3,4-dimethoxybicyclo[ 4.2.0]octa-1,3,5-triene-7-carboxylic acid and application in the synthesis of ivabradine and salts thereof.
UA111156C2 (en) METHOD OF SYNTHESIS OF IVABRADINE AND ITS ADDITIVE SALTS WITH PHARMACEUTICALLY ACCEPTABLE ACID